RecipientAmount (in million USD)Deal / Technology HighlightLead InvestorDeal TypeRecipient Country
Express Scripts 67,000To create an expanded portfolio of health services with greater choice, alignment and value across a proven services platformCigna CorporationAcquisitionUnited States
Novartis13,000Agreement with Novartis to buyout Novartis’ 36.5% stake in the Consumer Healthcare Joint Venture for $13 billion (£9.2 billion)GlaxoSmithKline plcJoint VentureSwitzerland
Eisai Co., Ltd.5,760Companies to Jointly Develop and Commercialize LENVIMA, as Monotherapy and in Combination with Merck & Co., Inc., Kenilworth, N.J., U.S.A.’s KEYTRUDA® (pembrolizumab) for Multiple Cancer TypesMerck & Co., Inc.,CollaborationJapan
Johnson & Johnson2,100Johnson & Johnson today announced that it has received a binding offer from Platinum Equity, a leading private investment firm, to acquire its LifeScan business for approximately $2.1 billion, subject to customary adjustments.Platinum EquityAcquisitionUnited States
Ionis Pharmaceuticals1,700Collaboration advances commercial readiness for planned mid-2018 inotersen launch, positioning Akcea to successfully launch two drugs for significant rare diseases this yearAkcea TherapeuticsLicensing AgreementUnited States
Prexton Therapeutics BV1,113Foliglurax is a first-in-class treatment, which entered clinical phase II testing in Parkinson’s disease in July 2017.H. Lundbeck A/SAcquisitionSwitzerland, Netherlands
Irvine Scientific Sales Company (ISUS) , IS Japan (ISJ)800The expected synergies are 1) the further expansion of the contact development and manufacturing business for biopharmaceuticals, 2) the acceleration of research and development in the area of regenerative medicine, and 3) the further expansion of reagent business.FUJIFILM CorporationAcquisitionJapan, United States
Nutranext700Nutranext’s products include multivitamins under the Rainbow Light® brand, the No. 2 vitamin brand in the natural channel1; specialty minerals under the Natural Vitality® brand, the No. 1 anti-stress and sleep brand in the natural channel2; and supplements for hair, skin and nails under the Neocell® brand. The Clorox CompanyAcquisitionUnited States
Pfizer Inc.590PF-04958242 is an AMPA receptor potentiator designed to facilitate neurotransmission for cognitive impairment associated with schizophrenia (CIAS).BiogenAsset Acquisition United States
CureTech553InSight will make an immediate payment of $50 million which will be used to fund development of CureTech’s immunotherapy candidate, which is currently geared towards the treatment of diffuse intrinsic pontine glioma (DIPG), a rare variety of brain tumour.InSight Biopharmaceuticals Ltd.AcquisitionIsrael
National Institute For Bioprocessing Research & Training462Shire, the Ireland-domiciled pharma group that specialises in rare diseases, has signed a training deal with the National Institute of Bioprocessing Research and Training (Nibrt) in Dublin. The €375 million investment will create the company’s European quality control hub for its biologics portfolio.Shire PLCTraining DealIreland
NxThera406Acquisition expands portfolio with minimally invasive treatment option for patients with benign prostatic hyperplasia. NxThera developed and commercialized, in the United States (U.S.) and Europe, the Rez?m® system which is a minimally invasive therapy in a growing category of treatment options for men with symptoms arising from BPHBoston ScientificAcquisitionUnited States
Arena Pharmaceuticals, Inc.406Arena anticipates using the net proceeds from the offering for the clinical and preclinical development of drug candidates, including its planned Phase 3 programs for etrasimod for the treatment of ulcerative colitis and ralinepag for the treatment of pulmonary arterial hypertension, for general corporate purposes, including working capital and costs associated with manufacturing services, and for capital expenditures.UndisclosedIPOUnited States
Heidelberg Pharma AG334The collaboration will combine Magenta’s stem cell platform with proprietary antibodies across up to four exclusive targets with Heidelberg Pharma’s proprietary ATAC (Antibody Targeted Amanitin Conjugates) platform.Magenta TherapeuticsResearch CollaborationGermany
C4X Discovery 294C4X Discovery signs licensing agreement with Indivior for addiction programme worth up to $294 million.Indivior PLCLicensing AgreementUnited Kingdom
Advanced Analytical Technologies, Inc. 250This acquisition will enhance Agilent's existing expertise and technology, while giving customers a more comprehensive set of solutions. AATI solutions are comprised of instruments, software and consumables aimed at simplifying complex workflows.Agilent Technologies Inc. AcquisitionUnited States
Cogentix Medical Inc.214The addition of Cogentix’s suite of technology will significantly expand LABORIE’S therapeutic offering, thereby providing customers and their patients with comprehensive, clinically-relevant solutions along the disease treatment continuum.LABORIE Medical TechnologiesAcquisitionCanada
Helix OpCo LLC200Helix operates one of the world’s largest CLIA-and-CAP-accredited Next Generation Sequencing laboratories. Powered by Illumina technologies, Helix uses its proprietary Exome+ assay to sequence each customer’s 20,000 protein-coding genes as well as additional information-rich areas identified by Helix’s scientific team.DFJ GrowthSeries B FinancingUnited States
Prothena Corporation plc 150Collaboration focuses on preclinical programs targeting proteins implicated in several neurodegenerative diseases, including tau, TDP-43 and an undisclosed third targetCelgene CorporationR&D CollaborationIreland
STEMCELL Technologies142 STEMCELL Technologies has signed an exclusive license with Indiana University Innovation and Commercialization Office for patented rights to groundbreaking inner ear organoid technologies.Indiana University Innovation and Commercialization OfficeLicensing AgreementCanada
Oxford Nanopore140Funding will support new manufacturing facility, commercial expansion, and development of new innovative products.GIC, CCB International, HostplusFinancingUnited Kingdom
Arcus Biosciences138Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist and an anti-PD-1 antibody, both of which are in Phase 1 trials, as well as a small molecule inhibitor of CD73 and an anti-TIGIT antibody, which are in IND-enabling studies.UndisclosedIPOUnited States
Aptose Biosciences125Aptose Biosciences Inc., a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced an exclusive global license agreement that provides OHM Oncology with the rights for the development, manufacture and commercialization of APL-581, as well as related molecules from Aptose’s dual bromodomain and extra-terminal domain motif (BET) protein and kinase inhibitor program. Aptose will retain reacquisition rights to certain moleOHM OncologyLicensing AgreementUnited States
TCR2 Therapeutics125Proceeds will support clinical development of lead program TC-210 and expansion of the multi-format TRuC™-T cell pipeline in solid tumors and blood cancers6 Dimensions Capital, MPM CapitalSeries B FinancingUnited States
Hua Medicine117The financing is expected to fully fund the Company through completion of its two Phase 3 trials and commercial launch in China for Dorzagliatin (HMS5552), a new first-in-class, 4th-generation glucokinase activator (GKA) that treats the impaired blood glucose sensor function, and thereby seeks to address the underlying cause of Type 2 diabetes.Blue Pool Capital, Alibaba GroupSeries D & Series E FinancingChina
Vividion Therapeutics101Collaboration utilizes Vividion’s unique proteome-wide ligand and target discovery platform.Celgene CorporationResearch CollaborationUnited States
Rubius Therapeutics100Proceeds from the financing will be used to accelerate the development of the Company’s portfolio of RCTs™ towards clinical proof-ofconcept, and to enhance its manufacturing capacity and capabilities.Flagship PioneeringCrossover FinancingUnited States
Tricida, Inc. 100This financing provides Tricida with significant financial flexibility as it continues the development of TRC101 for the treatment of metabolic acidosis in chronic kidney disease patientsHercules Capital, Inc.Venture Debt FinancingUnited States
Nabriva Therapeutics 95As part of the license agreement, Nabriva has granted a Roivant subsidiary an exclusive license to develop and commercialize lefamulin in the greater China region, specifically the People’s Republic of China, Hong Kong, Macau, and Taiwan.Roivant SciencesVenture Debt FinancingIreland
Ideaya Biosciences94Proceeds to advance multiple synthetic lethality and immuno-oncology therapies into the clinicNextech InvestSeries B FinancingUnited States
JW Therapeutics90By combining Juno’s world-class technology and platform with WuXi AppTec Group’s local expertise, R&D and manufacturing platform, and broader partnerships, JW Therapeutics has successfully initiated the development of its first CD19-directed investigational therapy, JWCAR029 (a CAR-T therapy being studied for the treatment of B-cell malignancies initially focusing on relapsed and refractory DCBCL).Temasek, Sequoia Capital China, YuanMing Capital etc.Series A FinancingChina
Tempus80The additional funds will be used to further grow and scale the company’s clinical and molecular analytic platform.New Enterprise AssociatesSeries D FinancingUnited States
Prevail Therapeutics75Prevail’s lead program, PR001, will be developed for a genetic subset of Parkinson’s disease and other mechanistically-related disorders.OrbiMedSeries A FinancingUnited States
Humacyte, Inc.75The funding is expected to support Humacyte’s ongoing HUMANITY study, the company’s pivotal Phase III study assessing the human acellular vessel (HAV), or HUMACYL®, as a conduit for hemodialysis in patients with end-stage renal disease who are not candidates for fistula placement.PointState CapitalSeries C FinancingUnited States
Evotec AG74Evotec-led platform expands current initiatives to accelerate research and development (“R&D”) of novel anti-infectives. Sanofi to licence more than 10 infectious disease R&D assets to evotec while retaining option rights for development and commercialisation. Sanofi SAResearch CollaborationGermany
Tempest Therapeutics70Proceeds from the Series B financing will support the advancement of lead program TPST-8844 into the clinic in the next 12 months as well as advancement of at least two other programs into the clinic shortly thereafter.Versant Ventures, F-Prime Capital, Quan CapitalSeries B FinancingUnited States
Crinetics Pharmaceuticals, Inc.64Crinetics Pharmaceuticals plans to use the proceeds to fund the continuing development of CRN00808, an oral nonpeptide somatostatin agonist for the potential treatment of acromegaly, to develop additional new targeted therapeutics for endocrine disorders and endocrine related cancers, and for general corporate purposes.Perceptive AdvisorsSeries B FinancingUnited States
Rheos Medicines60Founded by luminaries in the field of immunometabolism, Rheos aims to identify mechanisms and discover medicines that tune metabolic pathways in immune cells. Company’s therapeutics will focus on well-defined patient subsets in heterogeneous diseases including autoimmunity, inflammation and in immuno-oncology applications.Third Rock Ventures, LLCSeries A FinancingUnited States
BioXcel Therapeutics60The proceeds from the IPO will be used to fund the Phase II testing of the company's two most advanced drug candidates: BXCL501 and BXCL701. About $42 million of the total amount raised through the IPO will be used for Phase II research, with much of the remaining money slated to be used for working capital and for general corporate purposes, according to the company's SEC filing.UndisclosedIPOUnited States
Singlera Genomics60The funds will help Singlera expand the development and commercialization of its non-invasive genetic tests for early-stage cancer detection and clinical validation studies.Green Pine Capital PartnersSeries A FinancingUnited States, China
CARsgen Therapeutics60The funds will be used in support of Investigational New Drug submissions of several CAR-T therapeutics and Next-generation CAR-T research.UndisclosedPre-C Financing Framework AgreementChina
Xeris Pharmaceuticals55The proceeds from the two financings will help accelerate the development of additional product candidates applying Xeris’ ready-to-use glucagon to intermittent and chronic-use indications that require administration over a longer period.Silicon Valley BankSeries C Equity, Loan AgreementUnited States
Bristol-Myers Squibb Co55As part of the restructuring, Biohaven will pay BMS an upfront payment of $50 million in return for a low single digit reduction in the royalties payable on net sales of rimegepant and a mid-single digit reduction in the royalties payable on net sales of BHV-3500.Biohaven Pharmaceutical Holding Company Ltd.Restructures License Agreement United States
Unity Biotechnology55Proceeds from this financing will be used to advance the company's lead senolytic drug candidates into human clinical trials. UNITY Biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging.EcoR1 Capital Fund, 6 Dimensions CapitalSeries C FinancingUnited States
Mabion S.A.51Mabion intends to use the net proceeds from the financing to cover the cost of the expansion of production capacity in Konstantynów ?ódzki, Poland and costs and expenses related to the development and commercialization of Mabion CD20.European Bank For Reconstruction And Development (EBRD) And PFR Life Science Sp. Z O.O.Private PlacementPoland
CASI Pharmaceuticals, Inc.50The Company is working on its portfolio of 29 abbreviated new drug applications (ANDAs) (including 25 FDA-approved and 4 pending approval) that were recently acquired from Sandoz, and will continue to further expand the pipeline as part of their mission to bring innovative and high-quality medicines to the market.ETP Global Fund LP, IDG-Accel China Growth Fund IIIPrivate PlacementUnited States
Foghorn Therapeutics50Company’s Proprietary Gene Traffic ControlTM Product Platform Provides a New Way to Think About Treating Disease Flagship PioneeringCompany LaunchUnited States
Adagene Inc.50The funds from this round of financing will be used to advance novel antibody therapeutics into human trials across the globe. The antibodies discovered from our Dynamic Precision Library [DPL] platform enable translational research of our therapeutic leads on the intact immune system of highly predictive preclinical models.Sequoia ChinaSeries C FinancingChina
CBT Pharmaceuticals47The agreement gives CBT exclusive world-wide development and commercialization rights to a novel, recombinant, human monoclonal antibody which targets a differentiated epitope on the cytotoxic T-lymphocyte antigen-4 (CTLA-4) molecule. Binding of this antibody to CTLA-4 blocks the interaction of CTLA-4 with its ligands CD80/CD86 thus allowing the cytotoxic T cells to function actively.Crown Bioscience, Inc.Licensing AgreementUnited States
Inovio Pharmaceuticals43This collaboration of VGX-3100 encompasses the treatment and/or prevention of precancerous HPV infections and HPV-driven dysplasias (including cervical, vulvar and anal precancers) and excludes HPV-driven cancers and all combinations of VGX-3100 with other immunostimulants. The agreement also provides for potential inclusion of the Republic of Korea during the next three years.ApolloBio Corp.Licensing AgreementUnited States
TAE Life Sciences40TAE Life Sciences is leveraging TAE Technologies’ unique accelerator-based neutron beam technology for Boron Neutron Capture Therapy (BNCT) to bring promising treatment potential for head and neck, glioblastoma multiforme (GBM) and other cancers that are difficult or impossible to treat with traditional methods.Neuboron Medtech, Ltd., ARTIS VenturesSeries A FinancingUnited States
Dracen Pharmaceuticals, Inc.40Dracen will develop its glutamine antagonists both in single agent settings as well as in combination with immune checkpoint inhibitors such as anti-PD-1 and anti-PD-L1. The goal of these therapies is to increase the number of responders to anti-cancer therapy and extend survival; and potentially, to provide anti-tumor responses in areas currently evading immuno-oncology approaches.Deerfield ManagementSeries A FinancingUnited States
Themis Bioscience38First major investment by Coalition for Epidemic Preparedness Innovations (CEPI) to advance vaccine development and manufacturing on two of CEPI’s highest priority infectious diseases.Coalition for Epidemic Preparedness Innovations (CEPI)Non-Dilutive FundingNorway
Finch Therapeutics36.4The combination of the two biotechs also came with new support from Crestovo supporter Chris Shumway of Shumway Capital, who helped bring the syndicate together.TAKEDA, Shumway Capital, Willet Advisors, Morgan Noble and Avenir Growth CapitalSeries B FinancingUnited States
Adagene Inc.36The collaboration with WuXi Biologics will support supply of Adagene’s products for clinical trials under Investigational New Drug (IND) applications in both China and United States.WuXi Biologics, F-Prime Capital Research CollaborationChina
Bavarian Nordic36With funding from the DoD, Bavarian Nordic will utilize its proprietary MVA-BN® platform to develop a vaccine against various strains of the virus, for which there is currently no preventative vaccine treatment available. United States Department of Defense (DoD)PartnershipKingdom of Denmark
ViewPoint Therapeutics35ViewPoint plans to use the proceeds of the financing to develop its lead product candidate, VP1-001, through clinical proof-of-concept studies in patients with cataracts and presbyopia. In addition, ViewPoint anticipates that the proceeds will also allow the Company to advance second-generation compounds from its ongoing medicinal chemistry efforts.The Rise FundSeries B FinancingUnited States
Gelesis30The proceeds from the financing will be used to support commercial-stage manufacturing, product launch preparations, company operations, and clinical advancement of the Company’s pipeline of additional product candidates for gastrointestinal disorders, including Type 2 diabetes and non-alcoholic steatohepatitis/non-alcoholic fatty liver disease (NASH/NAFLD). The Company also plans to submit Gelesis100 for regulatory approvals in the US and Europe in 2018.PureTech HealthFinancingUnited States
AbCellera Biologics Inc.30Under DARPA’s Pandemic Prevention Platform (P3) program, AbCellera will apply its state-of-the art capabilities in human antibody discovery and immune profiling to establish rapid countermeasures for viral pandemics.Defense Advanced Research Projects Agency (DARPA)Multi-Year ContractCanada
Science 3729This three-year commitment will enable a more extensive portfolio of trials powered by the Network Oriented Research Assistant (NORA®), Science 37’s proprietary technology platform that enables patients to participate in clinical research regardless of their geographical location using mobile devices and telemedicine services.NovartisStrategic Alliance AgreementUnited States
Cyteir Therapeutics29Financing proceeds will be used to advance RAD51 inhibitor toward the clinic and expand small-molecule synthetic lethality platform for oncology and autoimmune diseases.Lightstone Ventures, DROIA Oncology Ventures, CelgeneSeries B FinancingUnited States
Kiadis Pharma N. V.29This €23.4 million private placement will fund the Company into H2 2019 and thus well beyond potential EU approval and into potential European launch of ATIR101™. UndisclosedPrivate PlacementNetherlands
Medeon Biodesign, Inc.20 Under the terms of the agreement, Terumo will pay US$20 million upfront and additional payments based on the achievement of future specific development milestones. It will be funded through cash on hand. Terumo CorporationAsset Purchase AgreementTaiwan
Cipher Pharmaceuticals20The Canadian business portfolio to be acquired by Cipher includes commercial and pipeline hospital products administered in the acute care setting, including Brinavess® (vernakalant IV), Aggrastat® (tirofiban hydrochloride), Xydalba™ (dalbavancin hydrochloride), andnTrevyent® a drug device combination that delivers treprostinil, the world's leading treatment for pulmonary arterial hypertension. Cardiome Pharma CorporationStrategic TransactionCanada
Escalier Biosciences19Escalier is developing both topical and oral ROR?t drug candidates for psoriasis and expects to be in the clinic with its topical compound in mid 2018.ForbionSeries B FinancingNetherlands
Minakem SAS18The €14.5M ($18M) investment from parent company Minafin is the first of this magnitude. It will enable the company to set up a new production line, increasing production capacity by 28m3.Minafin S.A.FinancingFrance
23Mofang (Chengdu 23 Magic Cube Biotechnology Co., Ltd.)16Maximum cost for the 23Mofang test is $158. Its biochip, which was co-developed with Thermo Fisher Scientific, tests for as many as 300 medical conditions. Proceeds from the newest round of financing will be used to enlarge its test centre, boost research and development of products, and expand further into the market.Matrix Partners ChinaSeries B FinancingChina
Arbor Biotechnologies, Inc.16Arbor’s discovery platform employs a diverse set of technologies and techniques – including artificial intelligence, genome sequencing, gene synthesis and high-throughput screening – to curate and mine the natural genetic diversity for impactful peptides, proteins, and enzymes. This approach enables systematic and high-throughput discovery of new molecules for improving human health and sustainability.ARCH Venture Partners, Faridan VenturesSeries A FinancingUnited States
Cullgen 15Cullgen's new drug discovery platform has the advantage of accelerating NCEs into clinical development in a cost and time efficient manner to benefit patients. Initial drug discovery programs will focus on oncology and expand into areas such as inflammatory and autoimmune diseases. GNI Group Ltd.Seed FundingUnited States, Japan
Oxford Vacmedix13Spun out by Oxford University Innovation in 2012, OVM is commercialising research led by Dr Shisong Jiang, ndeveloped as a partnership between Oxford University’s Department of Oncology and the Medical Research nCouncil’s Weatherall Institute of Molecular Medicine, also based in Oxford. The technology uses the novel, proprietary platform of recombinant overlapping peptides to design and develop therapeutic cancer vaccines and diagnostics with the potential for increased efficacy.Cancer Rop CoSeries A FinancingUnited Kingdom, China
Swift Medical12Already the market frontrunner with more than 1,000 facilities signed up across North America, Swift forges further ahead with plans to expand to every wound patient’s bedside.Data CollectiveSeries A FinancingCanada
twoXAR, Inc.10The proceeds will be used to build the company’s drug pipeline through partnerships and accelerate preclinical development of existing candidates.SoftBank Ventures, Andreessen Horowitz Bio Fund, OS FundSeries A FinancingUnited States
Veru Inc.10Under the terms of the deal, Veru received $10 million at closing and may receive an additional $2 million upon potential signing of tenders for FC2 Female Condom® product with two large international customers, subject to minimum units ordered.SWK HoldingsRoyalty FinancingUnited States
City of Hope National Medical Center6The City of Hope trial hopes to address this unmet medical need for adults with severe SCD.California Institute for Regenerative MedicineGrants & AwardsUnited States
Parachute Health6Health Tech Platform Revolutionizes $50 Billion Medical Equipment Industry by Reducing Hospital Costs & Improving Patient CareGreater New York Hospital Association Ventures, Loeb Holding CorporationSeed FundingUnited States
Immutep S.A.5Immutep Limited has announced that it has entered into a clinical trial collaboration and supply agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada), through a subsidiary, to evaluate the combination of Immutep’s lead immunotherapy product candidate eftilagimod alpha (“efti” or “IMP321”) with MSD's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in a new clinical trial that will evaluate the combination in several solid tumours. Merck & Co., Inc., Kenilworth, NJ, USA, Platinum Asset Management, Australian Ethical Investment, U.S., Ridgeback Capital InvestmentsClinical CollaborationAustralia
MicuRx Pharmaceutical Inc5The new agent MRX-8 is designed to overcome the limiting nephrotoxicity of current polymyxins. Current preclinical data demonstrated its high efficacy, with the reduced nephrotoxicity as well as attenuated acute or neuromuscular toxicity, when compared to existing polymyxin drugs.Combating Antibiotic Resistant Bacteria Accelerator (CARB-X)FinancingUnited States
Immuron Limited4Immuron has received a number of recent offers for financial support following the release of the Company’s positive top-line results of its IMM-124E Phase II Non-Alcoholic Steatohepatitis (NASH) clinical study.Joseph Gunnar & Co., LLCPrivate PlacementAustralia
BriaCell Therapeutics Corp.3The Company will use the proceeds from the Note Offering and the Non-Brokered Unit Offering, which includes investments from leading U.S. biotech funds such as Brio Capital Master Fund Ltd., Efrat Investments LLC and Mario Family Partners LP, to: (i) finance the Company’s Phase-2a clinical trial; (ii) to finance the Company’s pursuit of other research opportunities; and (iii) for working capital and general corporate purposes.Brio Capital Master Fund Ltd.,Securities Purchase AgreementCanada
PixCell Medical3The two-year award was granted through Horizon 2020's SME instrument, which targets high potential SMEs with groundbreaking products that have the potential to profoundly impact the EU economy and global healthcare.European CommissionGrants & AwardsIsrael
Metactive Medical, Inc.3This new investment capital and grant funding will be used to continue the development of Metactive's novel platform of embolic products, which we believe will provide physicians with devices that are exceptionally deliverable, can be placed with a high level of precision, are resistant to migration, and provide immediate, complete, and lasting occlusion.National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH), Mid-America Angels Capital Investment Network and Serra VenturesSeries A FinancingUnited States
Titan Pharmaceuticals, Inc. 2In addition to providing an opportunity to expand the commercialization of Probuphine beyond the United States, the additional financial resources and flexibility provided by this transaction enables Titan Pharma to evaluate options to further strengthen our balance sheet, position Probuphine for commercial success in the U.S., and work to advance our pipeline of other ProNeura™-based product candidates.L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A. Asset Purchase AgreementUnited States
Wellthy Therapeutics2Wellthy Therapeutics enables treatment of type-II diabetes using a hybrid of AI and human paramedical coaches to improve health literacy Manipal Education and Medical Group International India Pvt. Ltd. (MEMG)Series Seed FundingIndia
Laurent Pharmaceuticals Inc.2This new award is in addition to the US$ 3 million development award already committed by the CF Foundation to the Company. LAU-7b is a once-a-day oral pro-resolving therapy with potential to treat chronic pulmonary inflammation that leads to irreversible lung damage in patients with CF, regardless of their CFTR genotype.Cystic Fibrosis FoundationGrants & AwardsCanada
SemaThera Inc2SemaThera Inc announces today the closing of a $2MUS co-investment from Senju Pharmaceutical Co., Ltd. and AmorChem L.P. for the development of its lead candidate, ST-102, in preparation for a clinical trial application in diabetic macular edema (DME).Senju Pharmaceutical, AmorChemLicensing AgreementCanada
Amplia Therapeutics2In acquiring Amplia, Innate will acquire that company's Focal Adhesion Kinase (FAK) cancer programme. FAK is emerging as a promising target in cancer therapy.Innate ImmunotherapeuticsAsset Acquisition Australia
Cytox group1The project, ‘The development and implementation of polygenic risk scoring algorithms for stratifying individuals for future cognitive decline due to Alzheimer’s Disease in non-symptomatic and early cognitive impaired subjects’, will evaluate and validate the clinical utility of a customised genetic variation (single nucleotide polymorphism, SNP) panel associated with the development of Alzheimer’s disease (AD).Innovate UKFinancingEngland
RegeneRx Biopharmaceuticals, Inc.1RegeneRx, through its U.S joint venture, ReGenTree LLC, recently completed patient enrollment and treatment in its second Phase 3 clinical trial in approximately 600 patients with dry eye syndrome, reported positive clinical results, and has scheduled a meeting with the U.S. FDA in April 2018. Sabby Healthcare Master Fund, Ltd.,Warrant Reprice AgreementUnited States
Susan G. Komen®0.25The partnership between the three organizations has raised nearly $1 million to date, thanks to two earlier matching gift campaigns in 2016 and 2017.The Milburn Foundation, IBC Research FoundationDonationsUnited States
CNS Pharmaceuticals, Inc.0.12In a step toward democratizing the financing of a breakthrough cancer drug technology, CNS Pharmaceuticals, Inc., announced today the launch of its equity crowdfunding campaign on Republic, utilizing new equity crowdfunding securities laws called regulation CF or Reg CF for short, to support the development of Berubicin, its lead drug candidate for the treatment of Glioblastoma, the most aggressive type of brain cancer.UndisclosedCrowdfundingSwitzerland
Chiome BioscienceUndisclosedUnder this Agreement, Chiome grants SemaThera license to exclusively evaluate humanized anti-Semaphorin 3A antibody and an option right to obtain a worldwide exclusive license to use, develop and commercialize the Chiome's Antibody for both therapeutic and diagnostic uses.SemaThera IncDevelopment AgreementJapan
Pear TherapeuticsUndisclosedNovartis and Pear Therapeutics to collaborate on prescription software applications aimed to treat patients with schizophrenia and multiple sclerosis. Collaboration combines Novartis' leadership in biomedical research and clinical development with Pear's expertise in digital therapeutics. Novartis, 5AM VenturesPartnershipUnited States
PerlaraUndisclosedPerlara, a drug discovery platform company partnering with highly motivated families and drug developers to treat diseases thought too rare to attract the interest of pharmaceutical companies, today announced a collaboration with Harvard Medical School and the Undiagnosed Diseases Network to launch PerlQuests for two rare monogenic neurodevelopmental disorders.Undiagnosed Diseases NetworkResearch CollaborationUnited States
Hologic, Inc. UndisclosedPartnership will allow hospitals easier access to integrated suites of diagnostic imaging modalities, advanced informatics and services for comprehensive breast screening and diagnosisRoyal Philips PartnershipUnited States
MyBiotics Pharma Ltd.UndisclosedThis agreement follows the first agreement between the two parties signed in June 2017, for the validation of MyBiotics' technology in the treatment of a non-disclosed gastroenterology condition. Ferring HoldingLicensing AgreementIsrael
Autolus LimitedUndisclosedAutolus Limited, a U.K.-based biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, today announced the confidential submission of a draft registration statement on Form F-1 to the U.S. UndisclosedIPOUnited Kingdom
EMcision InternationalUndisclosedEMcision’s flagship product, the HabibTM EndoHPB, was the world’s first endoscopic device for tumour ablation via ERCP using radiofrequency energy in patients with advanced and inoperable pancreatic cancer and cholangiocarcinoma.Boston ScientificAcquisitionUnited Kingdom
Ligand Pharmaceuticals Incorporated, Poxel SA, Metavant SciencesUndisclosedLGD-6972 to be a foundational program for Metavant, a new company formed by Roivant to pursue the development of innovative therapies for cardiometabolic diseases.Roivant SciencesSetup / FoundingUnited States
ApexigenUndisclosedStudy to evaluate the safety and tolerability of APX005M, a CD40 agonistic antibody, in pediatric patients with recurrent or refractory brain tumorsPediatric Brain Tumor ConsortiumClinical CollaborationUnited States
Shire PlcUndisclosedLicense Expands Pipeline in Cardiovascular Disease based on Compelling Data Showing Improvement in Chest Pain, Exercise Capacity and MortalityCaladrius Biosciences, Inc.Licensing AgreementIreland
SelexisUndisclosedSelexis SUREtechnology Platform™ in use for the generation of high-performance research cell banks for CompugenCompugenLicensing AgreementSwitzerland
CDI LabsUndisclosedProteomics company leverages microarray capability to develop a high-throughput test that detects and discriminates between Zika and Dengue virusesJohns Hopkins, UPenn, Florida State UniversityResearch CollaborationUnited States
Surface OncologyUndisclosedUnder the terms of the agreement Surface Oncology will contract with ProBioGen to develop and manufacture another antibody for potential use in clinical trials. ProBioGen will develop several stable cell lines in parallel, gradually reduce the candidate number and conclude with process development and GMP manufacturing for a single antibody product candidateProBioGen AGManufacturing AgreementGermany
Integrated DNA TechnologiesUndisclosedIDT's primary business is the manufacturing of high-quality, custom DNA and RNA oligonucleotides serving customers in the academic and biopharmaceutical research, biotechnology, agriculture, clinical diagnostics, and pharmaceutical development end markets. Danaher CorporationAcquisitionSingapore
Regeneron PharmaceuticalsUndisclosedTo help ensure more affordable and timely access to patients most in need, Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi will offer payers that agree to reduce burdensome access barriers for high-risk patients a further reduced net price for Praluent® (alirocumab) Injection, in alignment with a new value assessment for high-risk patients from the Institute for Clinical and Economic Review (ICER) available here.Sanofi SALicensing AgreementUnited States, France
Lohmann Therapie-Systeme AGUndisclosedCurrently, Intec is producing the AP-CD/LD capsules for its Phase 3 clinical trial at its existing manufacturing facility in Jerusalem and will work together with LTS to establish commercial scale production capabilities for AP-CD/LD capsules.Intec Pharma Ltd.Manufacturing AgreementGermany, Israel
IO Biotech ApSUndisclosedIO Biotech’s lead candidate, IO102, is an IDO-derived immune modulating therapy with dual mode of action killing both cancer and immune-suppressive cells. IO Biotech’s IDO-derived immune modulating therapies have previously shown a favorable safety profile and signs of promising anti-tumor activity in a first in man trial of heavily pre-treated patients with NSCLC.Merck & Co., Inc., Kenilworth, NJ, USAClinical CollaborationDenmark
Lannett Company, IncUndisclosedInitially, the agreements cover one product from each partner, Diclofenac ER and Fluvastatin ER. Under the third agreement, Lannett will provide five of its currently marketed products to Pharmaceutical Associates, Inc. (PAI) for repackaging into unit dose cups and distribution into the managed care and hospital markets.Pharmaceutical Associates, Inc. (PAI), Undisclosed PartnerStrategic Alliance AgreementUnited States
Windtree Therapeutics, IncUndisclosedEleison has an exclusive worldwide license to inhaled lipid cisplatin (ILC), a novel, sustained release formulation of cisplatin in a nanoscale lipid-based complex administered via inhalation or intraperitoneally. Eleison Pharmaceuticals, Inc.Research CollaborationUnited States
IQVIAUndisclosedThe new initiative will be called the MOVR (NeuroMuscular ObserVational Research) Data Hub. The enhancements will capitalize on improvements in health care information technology and systemically unify and aggregate both clinical and genetics data with patient-reported information.Muscular Dystrophy Association (MDA)Disease Registry ExpansionUnited States
Natera, Inc.UndisclosedQIAGEN N.V., a world leader in providing Sample to Insight molecular solutions, and Natera, Inc., a leading developer of next-generation sequencing (NGS) assays that include non-invasive prenatal genetic testing and the analysis of circulating tumor DNA, today announced a partnership to develop cutting-edge cell-free DNA assays for use on QIAGEN’s GeneReader NGS System.QIAGEN N.V.PartnershipUnited States
Crown BioScienceUndisclosedPhanes will gain access to CrownBio’s clinically relevant CDX models, exclusive PDX models and robust in vitro assays to propel their innovative drug discovery pipeline.Phanes TherapeuticsPartnershipUnited States
Schott Kaisha Pvt LtdUndisclosedSCHOTT AG and Daikyo Seiko Ltd. are announcing that SCHOTT adaptiQ® vials and Daikyo PLASCAP® plastic press-fit closures are confirmed as a Product Set for use with Vanrx Pharmasystems’ Aseptic Filling Workcells.Vanrx Pharmasystems Inc.Strategic Alliance AgreementIndia
SanBio GroupUndisclosedSanBio is developing and pursuing the rapid commercialization in Japan and the US of its proprietary regenerative medicine product, SB623, as a new drug candidate for central nervous system disorders. Both the Phase 2b clinical trial of SB623 for the treatment of chronic motor deficit from ischemic stroke, which is being conducted in the US, and the Phase 2 global clinical trial of SB623 for the treatment of chronic motor deficit from traumatic brain injury (TBI), which is being conducted in JapHitachi Chemical Co., LtdJoint AgreementJapan
AmpliPhi BiosciencesUndisclosedThe agreement covers individual patient expanded access for AmpliPhi’s investigational bacteriophage therapeutics AB-SA01, targeting Staphylococcus aureus, and AB-PA01, targeting Pseudomonas aeruginosa.U.S. Department of Veterans AffairsResearch CollaborationUnited States
Ideaya BiosciencesUndisclosedIDEAYA Biosciences, Inc., an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines and immuno-oncology therapies, today announced that it has entered into a partnership agreement with Cancer Research UK’s (CRUK) Commercial Partnerships Team and the Drug Discovery Unit at the Cancer Research UK Manchester Institute, part of the University of Manchester, UK, to develop small molecule inhibitors of Poly(ADP-ribose) glycohydrolase (PARG).Cancer Research UKPartnershipUnited States
RxAdvanceUndisclosedCentene has had a long-standing commitment to providing comprehensive and integrated specialty services, including pharmacy management expertise provided through its Envolve division. Under this partnership, Centene and external customers will leverage Envolve's clinical competencies and RxAdvance's Collaborative PBM Cloud™ platform to deliver integrated, real-time, and data-driven pharmacy management services.Centene CorporationPartnershipUnited States
Avillion LLPUndisclosedAvillion has signed a co-development agreement with Pearl Therapeutics Inc., a wholly owned subsidiary of the AstraZeneca Plc group, to advance PT027 through a global clinical development programme for the treatment of asthma.Pearl Therapeutics Inc. (AstraZeneca plc)Co-Development AgreementUnited Kingdom
Sosei Group CorporationUndisclosedSosei Group, the world leader in GPCR medicine design and development, announced that it has regained worldwide rights from Teva Pharmaceutical Industries Ltd. to develop and commercialize lead candidate HTL0022562 and other novel small molecule CGRP antagonists for the treatment of migraine and other severe headaches.Teva Pharmaceutical Industries Ltd.Commercialization Agreement Japan
AveXis, Inc.UndisclosedIncludes exclusive worldwide rights to AAV9-SMN product and route of administrationGenethonLicensing AgreementUnited States
TARIS Biomedical LLCUndisclosedThis collaboration will focus on better understanding the natural history and disease outcomes for patients diagnosed with Muscle Invasive Bladder Cancer (MIBC), through analysis of Sweden’s National Registry of Urinary Bladder Cancer (SNRUBC) and BladderBaSe disease registries.Uppsala Clinical Research Center (UCR)Research CollaborationUnited States
ImmunoRestoration, Inc.UndisclosedThe agreement provides for ImmunoRestoration to commercialize certain intellectual property and technology related to the potential treatment of breast and other cancers.University of PennsylvaniaLicensing AgreementUnited States
Cancer Genetics Inc.UndisclosedThe partnership combines CGI’s Focus::NGS® offering, a suite of next generation sequencing (NGS) tests providing a comprehensive view of the patient genomic profile for both solid tumors and hematologic malignancies, with PierianDx’s integrated NGS workflow and analysis solution, Clinical Genomics WorkSpace™ (CGW), allowing for streamlined and accurate analysis, interpretation, and reporting.PierianDxPartnershipUnited States
Noramco, Inc.UndisclosedNoramco, Inc., a global leading producer of controlled substances for the pharmaceutical industry, and AMPAC Fine Chemicals (AFC), a major manufacturer of Active Pharmaceutical Ingredients (APIs) with cGMP facilities in the United States, today announced a strategic partnership to produce certain US DEA controlled substances for use in the treatment of addiction, abuse prevention, cannabinoids for clinical indications, and for the treatment of attention deficit hyperactivity disorder (ADHD).AMPAC Fine Chemicals (AFC)PartnershipUnited States
Continuum Clinical, LLC, UndisclosedCompany Expands Worldwide Evidence™ Observational Research Services, Adds Health Economics Outcomes Research (HEOR) and Patient Registry CapabilitiesWorldwide Clinical TrialsAcquisitionUnited States
LenioBio GmbHUndisclosedLenioBio will market the innovation to bio-pharmaceutical developers under the brand name ALiCE™.Dow AgroSciences LLCLicensing AgreementUnited States, Germany
Martin PharmaceuticalsUndisclosed Two accomplished healthcare executives, David Martin Geliebter and Sven Martin Jacobson, founders of Remedy Pharmaceuticals, announced the launch of Martin Pharmaceuticals, with the mission of repurposing already-approved drugs in order to offer life-changing advances to patients afflicted with rare (orphan) diseases or challenging medical conditions. Martin is the sixth healthcare company the pair has started since 2001.UndisclosedSeed FundingUnited States
IntegenX, Inc.UndisclosedIntegenX solutions include the RapidHIT platforms, software analysis tools and related consumables that are highly compatible with Thermo Fisher's short tandem repeat (STR) chemistries for human identification.Thermo Fisher Scientific Inc.AcquisitionUnited States
Intezyne Technologies, Inc.UndisclosedIntezyne, a clinical-stage biopharmaceutical company developing novel anti-cancer therapies, announced that it has partnered with Exosome Diagnostics, a privately held company focused on developing and commercializing revolutionary biofluid-based diagnostics, to design and validate an assay for use in Intezyne's upcoming Phase 1/2 clinical trials of IT-139, a novel Cancer Resistance Pathway (CRP) inhibitor for the treatment of pancreatic, gastric and other cancers in combination with existing aExosome Diagnostics, IncPartnershipUnited States
Nexcelom Bioscience LLCUndisclosedThe funding will be primarily used to support Nexcelom’s worldwide growth initiatives. Founded in 2003, Nexcelom is a fast-growing supplier of innovative cellular analysis instruments, software and related consumables used in a broad range of research fields including immuno-oncology, cell therapy, drug discovery, vaccine development and manufacturing, and therapeutic cell line generation.Ampersand Capital PartnersStrategic InvestmentUnited States
Celltrion HealthcareUndisclosedThird biosimilar deal with Celltrion Healthcare cements Mundipharma’s leadership position in the biosimilar market and is testament to Mundipharma’s commercializationnexpertise.Mundipharma International LimitedPartnershipSouth Korea
Hirokodo Pharmaceutical Co., Ltd.UndisclosedBased on scientific evidence, Shin Kowato Pharmaceutical aims seriously for the worldwide realization of productive aging.Shinkowa Pharmaceutical Co., LtdAcquisitionJapan
Alnylam Pharmaceuticals, Inc.UndisclosedCollaboration based on new findings from the Regeneron Genetics Center® showing variant in HSD17B13 gene is associated with reduced risk of chronic liver diseasesRegeneron Pharmaceuticals, Inc.Research CollaborationUnited States
International Myeloma Foundation (IMF)UndisclosedStudy is among the largest and most comprehensive in multiple myeloma (MM), and will assess outcomes from 1,500 patients with MM and the t(11;14) translocation at participating International Myeloma Foundation sites globally.AbbVie OncologyPartnershipUnited States
EnDev LaboratoriesUndisclosedTergus Has Added Early Development & Skin Biology Capabilities with EnDev LaboratoriesTergus Pharma AcquisitionUnited States
Innate Biologics, LLCUndisclosedThe therapeutic platform is being developed to treat inflammation associated with auto-immune conditions such as asthma, rheumatoid arthritis, psoriasis, obesity, idiopathic pulmonary fibrosis, ulcerative colitis and Crohn’s disease, and other conditions and syndromes characterized by activation of inflammatory pathways. The Wistar InstituteResearch CollaborationUnited States
Syngene InternationalUndisclosedSyngene scientists to work with GSK to advance drug discovery in multiple therapeutic areasGlaxoSmithKline plcR&D AgreementIndia
Aslan PharmaUndisclosedASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its American Depository Shares (ADSs) in the United States.UndisclosedIPOSingapore
Arpeggio BiosciencesUndisclosedData generated in this collaboration could enable FORMA to better understand the translational utility of its small molecule pipeline of therapeutics targeting cancer and other serious diseases.FORMA TherapeuticsResearch CollaborationCanada
NanoMedSynUndisclosedResearch agreement focuses on evaluating a potential treatment for a lysosomal storage disorder using NanoMedSyn’s proprietary AMFA technologyShire PLCClinical CollaborationFrance
OncoDNAUndisclosedOncoDNA, the Cancer Theranostic Company, said today that it has inked a distribution agreement with PromTest LLC (Armenia), a company offering a wide range of high-quality clinical, molecular testing services to meet diagnostic and treatment planning requirements.PromTest LLCDistribution AgreementBelgium
ACI ClinicalUndisclosedACI Clinical will continue to operate as an independent service organization within the Clinical Services Division. WCG will support ACI Clinical as it continues to expand, with access to capital, complementary clinical and regulatory expertise, and corporate support.WCG (WIRB-Copernicus Group) Clinical Services Division AcquisitionUnited States
Ascendance Biotechnology, Inc. (Hepregen & ESI BIO, Inc.)UndisclosedBioIVT is adding Hepregen’s HepatoPac®, HepatoMune™ and HepatoStem™ liver cell and stem cell product lines to its drug safety testing and toxicology portfolios.BioIVTAcquisitionUnited States
Biocept UndisclosedCollaboration plans to establish Biocept as Thermo Fisher Center of Excellence for liquid biopsy and to pursue commercial opportunities in both pharmaceutical and clinical marketsThermo Fisher Scientific Inc.Commercialization Agreement United States
Nichi-Iko PharmaceuticalUndisclosedUnder the agreement, Eisai will transfer all shares of Eisai’s wholly-owned subsidiary Elmed Eisai Co., Ltd. (Headquarters: Tokyo, “Elmed Eisai”) to Nichi-Iko incrementally in accordance with progress of the strategic alliance agreement, and both companies will promote cooperation in building Eisai’s Total Inclusive Ecosystem as well as collaboration on the active pharmaceutical ingredient (API) business promoted primarily at Eisai’s Vizag Plant in India.Eisai Co., Ltd. (Elmed Eisai)Strategic Alliance AgreementJapan
bluebird bio., IncUndisclosedbluebird bio, Inc. and Celgene Corporation today announced that the companies have entered into an agreement to co-develop and co-promote bb2121, an investigational anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy for the potential treatment of patients with relapsed/refractory multiple myeloma in the United States.Celgene CorporationCo-Development AgreementUnited States
Abide TherapeuticsUndisclosedAbide Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting the serine hydrolase family of enzymes, announced today it has granted Celgene an exclusive worldwide license for ABX-1772, a preclinical drug candidate discovered by Abide.Celgene CorporationLicensing AgreementUnited States
Unum PharmaUndisclosedUnum Therapeutics is actively building a pipeline of ACTR programs in combination with a wide range of proprietary, tumor-targeting antibodies for use in both hematologic and solid tumor cancers.UndisclosedIPOUnited States
Actinium Pharmaceuticals UndisclosedCollaborative research agreement will utilize Actinium’s AWE Technology Platform to generate Actinium Radio-Conjugates on selected Astellas targeting agentsAstellas Pharma Inc.Research CollaborationUnited States
Ligand Pharmaceuticals IncorporatedUndisclosedOmniAb is a three-species transgenic-animal platform consisting of four different technologies used for producing mono- and bispecific human therapeutic antibodies. venBio PartnersLicensing AgreementUnited States
CutisPharma, Inc.UndisclosedCutisPharma, Inc., a specialty pharmaceutical company that for two decades has been the industry leader in providing innovative solutions to pharmacists, with its recently approved 505(b)(2) NDA for FIRVANQ™ vancomycin oral solution kit by the FDA, today announced that it has been acquired by NovaQuest Capital Management, L.L.C. NovaQuest Capital Management, L.L.C.AcquisitionUnited States
Molecular Response LLCUndisclosedBioDuro LLC, a leading global life sciences contract research and development organization, announced today the acquisition of Molecular Response LLC and its world-class translational oncology research platform, including its biobank of >100,000 viable tumor specimens. BioDuro LLCAcquisitionUnited States
Daiichi Sankyo, Inc.UndisclosedNew campaign "Get Iron Informed" aims to educate people about Iron Deficiency Anemia, a condition that affects 36 to 76 percent of people with inflammatory bowel diseases.Crohn's & Colitis Foundation CollaborationJapan
ChemConnection B.V.UndisclosedThis announcement follows a series of acquisitions by Belgium-headquartered Ardena and is part of its strategy to form a leading integrated drug development company and reach the €30m sales mark this year.Ardena AcquisitionNetherlands